Balaji Amines reported revenue of ₹336 Crore and EBITDA of ₹62 Crore for Q3FY26. Net profit stood at ₹31 Crore. The company highlighted stable operational performance supported by stable commodity prices and consistent demand across key segments. Expansion projects are progressing as planned, with new capacities expected to contribute to future growth. The company is confident about leveraging India’s push for self-sufficiency in specialty chemicals.
Q3FY26 Financial Highlights
Balaji Amines announced its unaudited financial results for the quarter ended December 31, 2025. Key highlights include:
- Consolidated Revenue: ₹336 Crore
- EBITDA: ₹62 Crore
- Net Profit: ₹31 Crore
The company witnessed stable operational performance due to consistent demand and stable commodity prices.
9MFY26 Performance Overview
The cumulative performance for the first nine months of FY26 is as follows:
- Total Income: ₹1,051.26 Crore
- EBITDA: ₹192.25 Crore
Segmental Volumes
For Q3FY26, the sales volumes were:
- Amines: 6,993.27 MT
- Amines Derivatives: 9,222.55 MT
- Specialty Chemicals: 9,678.27 MT
Expansion and Future Outlook
The company is progressing with its expansion projects, including:
- Di Methyl Ether (DME) plant: Expected commissioning in FY 2026-27.
- N-Methyl Morpholine (NMM) plant: Expected commissioning in FY 2026-27.
- Acetonitrile (ACN) plant: Expected commissioning in FY 2026-27.
Balaji Amines is also undertaking a major expansion project worth ₹750 Crores in its subsidiary, Balaji Speciality Chemicals Limited. This includes manufacturing a wide range of products like Hydrogen Cyanide (HCN) and Sodium Cyanide (NaCN).
The company remains optimistic about leveraging opportunities arising from domestic import-substitution trends and India’s push for self-sufficiency in specialty chemicals.
Source: BSE
